The combination of Nivolumab + Ipilimumab (anti-PD-1 + anti-CTLA-4 antibodies) manages to provide survival rates of over 50% at 5 years for cases of metastatic melanoma [9]. Here, CTLA4 is linked to metastatic melanoma.